Cited by 257CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Mailankody, Sham, Matous, Jeffrey V., Chhabra, Saurabh, Liedtke, Michaela, Sidana, Surbhi, Oluwole, Olalekan O., Malik, Shahbaz, Nath, Rajneesh, Anwer, Faiz, Cruz, Jose Carlos, Htut, Myo, Karski, Erin E., Lovelace, Wade, Dillon, Myles, Butz, Eric, Ying, Wendy, Balakumaran, Arun, Kumar, Shaji K.·2023·Nature Medicine

DOI 10.1038/s41591-022-02182-7

Open this paper in CoChat — free account

Abstract

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial. Primary objectives included determination of the safety and tolerability of ALLO-715 and the safety profile of the ALLO-647-containing lymphodepletion regimen. Key secondary endpoints were response rate and duration of response. Grade ≥3 adverse events were reported in 38 (88.0%) of patients. Cytokine release syndrome was observed in 24 patients (55.8%), with 1 grade ≥3 event (2.3%) and neurotoxicity in 6 patients (14%), with no grade ≥3 events. Infections occurred in 23 patients (53.5%), with 10 (23.3%) of grade ≥3. Overall, 24 patients (55.8%) had a response. Among patients treated with 320 × 10 6 CAR+ T cells and a fludarabine-, cyclophosphamide- and ALLO-647-based lymphodepletion regimen (n = 24), 17 (70.8%) had a response including 11 (45.8%) with very good partial response or better and 6 (25%) with a complete response/stringent complete response. The median duration of response was 8.3 months. These initial results support the feasibility and safety of allogeneic CAR T cell therapy for myeloma.

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02182-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citation
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citation
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citation
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 667
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citation

Show all 31 references

Research works printed but not linked: 1

Prevention and Treatment of Cancer-Related Infections (Version 3.2022). NCCN Clinical Practice Guidelines in Oncology, Vol. 2022 (National Comprehensive Cancer Network, 2022).

Sorted by citations

Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,503
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q. F., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 526
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 443
CAR T Cells and T-Cell Therapies for Cancer
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 412
Current understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 352
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 291
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Qi, C., Liu, C., Gong, J., Liu, D., Wang, X., Zhang, P., Qin, Y., Ge, S., Zhang, M., Peng, Z., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03037-z · Cited by 235
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
Lickefett, B., Chu, L., Ortiz‐Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D. A., Hudecek, M., Kremer, A., Markman, J. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 200
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Zhang, X., Zhang, H., Lan, H., Wu, J., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101495 · Cited by 181
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 168
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method
Li, Y.-R., Zhou, Y., Yu, J., Kim, K. G., Li, M., Lee, D., Zhou, K., Chen, Y., Zhu, Y., Wang, Y.-C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02226-y · Cited by 131
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 122
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Lonez, C., & Breman, E. (2024) · Cells · doi:10.3390/cells13020146 · Cited by 119
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
Oliver‐Caldés, A., González‐Calle, V., Cabañas, V., Español‐Rego, M., Rodríguez‐Otero, P., Reguera, J. L., López‐Corral, L., Martín-Antonio, B., Zabaleta, A., Inogés, S., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00222-x · Cited by 98
CAR T cells for treating autoimmune diseases
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D., & Fricke, S. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002907 · Cited by 98
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Diorio, C. J., Teachey, D. T., & Grupp, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00959-y · Cited by 95
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Swan, D., Madduri, D., & Hocking, J. S. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01191-8 · Cited by 110
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 89
Self-citation
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Lin, Y., Qiu, L., Usmani, S. Z., Joo, C. W., Costa, L. J., Derman, B. A., Du, J., Einsele, H., de Larrea, C. F., Hájek, R., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00094-9 · Cited by 79
Self-citation
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
Wei, W., Chen, Z., & Wang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512317 · Cited by 90
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 84
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications
Feng, X., Li, Z. Y., Liu, Y., Chen, D., & Zhou, Z. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00570-y · Cited by 86
Expanding access to CAR T cell therapies through local manufacturing
Elsallab, M., & Maus, M. V. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01981-8 · Cited by 81
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
Li, Y.-R., Zhou, Y., Yu, J., Zhu, Y., Lee, D., Zhu, E., Li, Z., Kim, Y. J., Zhou, K., Fang, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.005 · Cited by 73
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Lv, Z., Luo, F., & Chu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199145 · Cited by 70
Emerging trends in clinical allogeneic CAR cell therapy
Li, Y.-R., Zhu, Y., Fang, Y., Lyu, Z., & Yang, L. (2025) · Med · doi:10.1016/j.medj.2025.100677 · Cited by 72
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Kilgour, M. K., Bastin, D. J., Lee, S., Ardolino, M., McComb, S., & Visram, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166038 · Cited by 66
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
Managing allorejection in off-the-shelf CAR-engineered cell therapies
Li, Y.-R., Fang, Y., Niu, S., Chen, Y., Lyu, Z., & Yang, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.035 · Cited by 65
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
Li, Y.-R., Fang, Y., Niu, S., Zhu, Y., Chen, Y., Lyu, Z., Zhu, E., Tian, Y., Huang, J., Rezek, V. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56270-6 · Cited by 62
Engineering immune-evasive allogeneic cellular immunotherapies
Martin, K. E., Hammer, Q., Perica, K., Sadelain, M., & Malmberg, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01022-8 · Cited by 64
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer
Lyu, Z., Niu, S., Fang, Y., Chen, Y., Li, Y.-R., & Yang, L. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00654-3 · Cited by 61
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Markouli, M., Ullah, F., Unlu, S., Omar, N., Lopetegui-Lia, N., Duco, M. R., Anwer, F., Raza, S., & Dima, D. (2023) · Current Oncology · doi:10.3390/curroncol30070467 · Cited by 51
Self-citation
Recent updates on allogeneic CAR-T cells in hematological malignancies
Mansoori, S., Noei, A., Maali, A., Seyed-Motahari, S. S., & Sharifzadeh, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03479-y · Cited by 57
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Yang, C., Sun, C., Tan, B., Hu, C., Wan, L., Wang, C., Shi, X., Qin, J., Zhang, N., Zheng, B., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01128-1 · Cited by 51
Metabolic engineering for optimized CAR-T cell therapy
McPhedran, S. J., Carleton, G. A., & Lum, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00976-2 · Cited by 51
Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
Luo, J., & Zhang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1399544 · Cited by 48
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
Gu, X., Zhang, Y., Zhou, W., Wang, F., Yan, F., Gao, H., & Wang, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00542-2 · Cited by 49
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
An, N., Wang, D., Zhang, P., Zhang, J., Parone, P. A., Hu, J., Bao, Y., Xu, L., Ruan, H., Wan, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04244-6 · Cited by 57
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances
Chen, S., & van den Brink, M. R. M. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101566 · Cited by 51
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 46
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
Connolly, K., Brungs, D., Szeto, E., & Epstein, R. J. (2013) · Current Oncology · doi:10.3747/co.21.1661 · Cited by 42
The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy
Abou‐El‐Enein, M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0272 · Cited by 45
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
Genetically engineered hypoimmunogenic cell therapy
Hotta, A., Schrepfer, S., & Nagy, A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00219-9 · Cited by 44
CAR T-cell therapy in multiple myeloma: mission accomplished?
Rasche, L., Hudecek, M., & Einsele, H. (2023) · Blood · doi:10.1182/blood.2023021221 · Cited by 44
Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update
Bellal, M., Malherbe, J., Damaj, G. L., & du Cheyron, D. (2024) · Critical Care · doi:10.1186/s13054-024-04851-0 · Cited by 42
New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication
Qin, S., Xie, B., Wang, Q., Yang, R., Sun, J., Hu, C., Liu, S., Tao, Y., & Xiao, D. (2024) · MedComm · doi:10.1002/mco2.551 · Cited by 40
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 38
CAR-T cell combination therapies in hematologic malignancies
Zhou, D., Zhu, X., & Xiao, Y. Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00536-0 · Cited by 39
High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
Degagné, É., Donohoue, P. D., Roy, S., Scherer, J., Fowler, T. W., Davis, R. T., Reyes, G. A., Kwong, G., Stanaway, M., Vicena, V. L., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0679 · Cited by 35
Noncanonical and mortality-defining toxicities of CAR T cell therapy
Rejeski, K., Hill, J. A., Dahiya, S., & Jain, M. D. (2025) · Nature Medicine · doi:10.1038/s41591-025-03813-5 · Cited by 42
Recent advances in universal chimeric antigen receptor T cell therapy
Jiang, N., Yang, Z., Miao, H., Xing, S., Wang, S., & Li, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01737-8 · Cited by 41
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Mei, J., Liu, X., Tian, H., Chen, Y., Cao, Y., Zeng, J., Liu, Y., Chen, Y., Gao, Y., Yin, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1656 · Cited by 34
CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer
Nasiri, F., Farrokhi, K., Kozani, P. S., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1302307 · Cited by 32
Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
Xiong, D., Yu, H., & Sun, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.022 · Cited by 31
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Costa, B. A., Flynn, J. R., Nishimura, N., Devlin, S. M., Farzana, T., Rajeeve, S., Chung, D. J., Landau, H. J., Lahoud, O. B., Scordo, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01048-0 · Cited by 34
Self-citation
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
Mog, B. J., Marcou, N., DiNapoli, S. R., Pearlman, A. H., Nichakawade, T. D., Hwang, M. S., Douglass, J., Hsiue, E. H.-C., Glavaris, S. A., Wright, K. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7123 · Cited by 31
Leukapheresis for CAR-T cell production and therapy
Pessach, I., & Nagler, A. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103828 · Cited by 32
HIV immune evasin Nef enhances allogeneic CAR T cell potency
Perica, K., Kotchetkov, I. S., Mansilla‐Soto, J., Ehrich, F. D., Herrera, K., Shi, Y., Dobrin, A., Gönen, M., & Sadelain, M. (2025) · Nature · doi:10.1038/s41586-025-08657-0 · Cited by 29
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network.
van de Donk, N. V., Moreau, P., San-Miguel, J., Mateos, M.-V., Dimopoulos, M., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 26
Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy
Chen, Y., Zhu, Y., Kramer, A. B., Fang, Y., Wilson, M., Li, Y.-R., & Yang, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1135468 · Cited by 26
FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges
Ong, M. Z., Kimberly, S. A., Lee, W.-H., Ling, M., Lee, M., Tan, K.-W., Foo, J. B., Yow, H.-Y., Sellappans, R., & Hamzah, S. B. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010257212231001082741 · Cited by 29
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies
Su, J.-C., Zeng, Y., Song, Z., Liu, Y., Ou, K., Wu, Y., Huang, M., Li, Y., & Tu, S. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01745-8 · Cited by 29
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia
Calviño, C., Ceballos, C., Piérola, A. A., Jáuregui, P., Calleja-Cervantes, M. E., Martín‐Úriz, P. S., Rodríguez-Márquez, P., Martín-Mallo, Á., Iglesias, E., Abizanda, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270843 · Cited by 26
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 23
Allogeneic CART progress: platforms, current progress and limitations
Shokati, A., Sanjari-Pour, M., Rahnama, M. A., Hoseinzadeh, S., Vaezi, M., & Ahmadvand, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557157 · Cited by 29
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. (.-T., Tariq, M., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C., Valent, J., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 25
Self-citation
Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities
Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 28
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them
Rees, M. J., & Kumar, S. K. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2284088 · Cited by 22
Self-citation
iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Hui, K. K., & Yamanaka, S. (2024) · BioEssays · doi:10.1002/bies.202400072 · Cited by 23
Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
Wachsmann, T. L. A., Meeuwsen, M. H., Remst, D. F. G., Buchner, K., Wouters, A. K., Hagedoorn, R. S., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010410 · Cited by 22
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Oliver‐Caldés, A., Español‐Rego, M., Zabaleta, A., González‐Calle, V., Velázquez, S. N., Inogés, S., de Cerio, A. L.-D., Cabañas, V., López‐Muñoz, N., Rodríguez‐Otero, P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3759 · Cited by 21
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Lu, Q., Li, H., Wu, Z., Zhu, Z., Zhang, Z., Yang, D., & Tong, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02512-6 · Cited by 19
Current use of CAR T cells to treat multiple myeloma
Firestone, R., & Mailankody, S. (2023) · Hematology · doi:10.1182/hematology.2023000434 · Cited by 18
Self-citation
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy
Huang, J., Yang, Q., Wang, W., & Huang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378739 · Cited by 18
Allogeneic CAR T Cell Therapy for Cancer
Sasu, B. J., Lauron, E. J., Schulz, T. F., Cheng, H., & Sommer, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-023316 · Cited by 16
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
Tacchetti, P., Talarico, M., Barbato, S., Pantani, L., Mancuso, K., Rizzello, I., Zamagni, E., & Cavo, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344647 · Cited by 16
Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
An, J., Zhao, J., Zou, P., Zhang, Y., Wei, J., Tian, W., & Wei, J. (2024) · Cancer Medicine · doi:10.1002/cam4.7372 · Cited by 16
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Georgiadis, C., Preece, R., & Qasim, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.040 · Cited by 17
Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma
Lu, Q., Yang, D., Li, H., Zhu, Z., Zhang, Z., Chen, Y., Yang, N., Li, J., Wang, Z., Niu, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216660 · Cited by 15
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 19
T-cell exhaustion in multiple myeloma
Żyłka, K., Kubicki, T., Gil, L., & Dytfeld, D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2370552 · Cited by 15
Bispecific antibody targets and therapies in multiple myeloma
Rees, M. J., Abdallah, N., Yohannan, B., & Gonsalves, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424925 · Cited by 16
Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression
Li, W., Chen, J., Li, J., Wang, S., Chen, Z., Zhao, L., Zhao, Y., Gu, L., Liu, J., Zhang, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012321 · Cited by 14
Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma
Bal, S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.19227 · Cited by 14
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
Wang, Q., Wei, R., Guo, S.-F., Min, C., Zhong, X., Huang, H., & Zhi, C. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00712-0 · Cited by 14
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations
Martín-Antonio, B., Blanco, B., González‐Murillo, Á., Hidalgo, L., Minguillón, J., & Pérez-Chacón, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386856 · Cited by 14
Beyond BCMA: newer immune targets in myeloma
Tan, M. S. Y., Chen, Y.-X., & Smith, E. L. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010856 · Cited by 12
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15
Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models
Lin, R., Sutton, J. E., Bentley, T., Vargas‐Inchaustegui, D. A., Nguyen, D., Cheng, H., Yoon, H., Blarcom, T. J. V., Sasu, B. J., Panowski, S. H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg8694 · Cited by 14
The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib
Tang, S., Zhang, F., Li, J., Dong, H., Yang, Q., Liu, J., & Fu, Y. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110687 · Cited by 13
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 13
Self-citation
Clinical Pharmacology Considerations for the “ Off‐the‐Shelf ” Allogeneic Cell Therapies
Mody, H. R., Sutaria, D. S., & Miles, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3241 · Cited by 14
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 16
Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies
Michaels, Y. S., Durland, L. J., & Zandstra, P. W. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0008 · Cited by 12

Authors: Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, W., Dillon, M., Butz, E., Ying, W., Balakumaran, A., & Kumar, S. K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Colorado Blood Cancer Institute (US)
Medical College of Wisconsin (US)
Stanford Medicine (US)
Vanderbilt University Medical Center (US)
St David's Medical Center (US)
Banner MD Anderson Cancer Center (US)
Cleveland Clinic (US)
City Of Hope National Medical Center (US)
Allogene Therapeutics (United States) (US)
Mayo Clinic (US)
Corresponding author: Mailankody, Sham
ORCID: Mailankody, Sham
Chhabra, Saurabh
Liedtke, Michaela
Sidana, Surbhi
Oluwole, Olalekan O.
Malik, Shahbaz
Nath, Rajneesh
Anwer, Faiz
Htut, Myo
Ying, Wendy
Kumar, Shaji K.
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2023-01-23
Volume: 29
Issue: 2
Pages: 422-429
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-022-02182-7
OpenAlex: W4317802192
Cited by: 257
References: 31
Citations by year: 2026: 42 · 2025: 57 · 2024: 96 · 2023: 60
FWCI: 31.02
Type: journal article
Language: en
Update notices: correction (2023-03-17)
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA008748)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: allogeneic CAR T cells, BCMA, multiple myeloma, relapsed/refractory multiple myeloma, anti-CD52 antibody, lymphocyte depletion, graft-versus-host disease prophylaxis, cytokine release syndrome, neurotoxicity, safety and tolerability, response rate, duration of response
MeSH terms: Cyclophosphamide, Humans, Multiple Myeloma, T-Lymphocytes, Immunotherapy, Adoptive, Hematopoietic Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks